Literature DB >> 26446169

A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.

Anguraj Sadanandam1, Stephan Wullschleger2, Costas A Lyssiotis3, Carsten Grötzinger4, Stefano Barbi5, Samantha Bersani5, Jan Körner4, Ismael Wafy2, Andrea Mafficini5, Rita T Lawlor5, Michele Simbolo5, John M Asara6, Hendrik Bläker7, Lewis C Cantley3, Bertram Wiedenmann4, Aldo Scarpa8, Douglas Hanahan9.   

Abstract

UNLABELLED: Seeking to assess the representative and instructive value of an engineered mouse model of pancreatic neuroendocrine tumors (PanNET) for its cognate human cancer, we profiled and compared mRNA and miRNA transcriptomes of tumors from both. Mouse PanNET tumors could be classified into two distinctive subtypes, well-differentiated islet/insulinoma tumors (IT) and poorly differentiated tumors associated with liver metastases, dubbed metastasis-like primary (MLP). Human PanNETs were independently classified into these same two subtypes, along with a third, specific gene mutation-enriched subtype. The MLP subtypes in human and mouse were similar to liver metastases in terms of miRNA and mRNA transcriptome profiles and signature genes. The human/mouse MLP subtypes also similarly expressed genes known to regulate early pancreas development, whereas the IT subtypes expressed genes characteristic of mature islet cells, suggesting different tumorigenesis pathways. In addition, these subtypes exhibit distinct metabolic profiles marked by differential pyruvate metabolism, substantiating the significance of their separate identities. SIGNIFICANCE: This study involves a comprehensive cross-species integrated analysis of multi-omics profiles and histology to stratify PanNETs into subtypes with distinctive characteristics. We provide support for the RIP1-TAG2 mouse model as representative of its cognate human cancer with prospects to better understand PanNET heterogeneity and consider future applications of personalized cancer therapy. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26446169      PMCID: PMC4946251          DOI: 10.1158/2159-8290.CD-15-0068

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  66 in total

1.  Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors.

Authors:  Yu Takahashi; Yuri Akishima-Fukasawa; Noritoshi Kobayashi; Tsuyoshi Sano; Tomoo Kosuge; Yuji Nimura; Yae Kanai; Nobuyoshi Hiraoka
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

2.  Impact of normalization on miRNA microarray expression profiling.

Authors:  Sylvain Pradervand; Johann Weber; Jérôme Thomas; Manuel Bueno; Pratyaksha Wirapati; Karine Lefort; G Paolo Dotto; Keith Harshman
Journal:  RNA       Date:  2009-01-28       Impact factor: 4.942

3.  Induction of angiogenesis during the transition from hyperplasia to neoplasia.

Authors:  J Folkman; K Watson; D Ingber; D Hanahan
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

Review 4.  Neuroendocrine neoplasms of the gut and pancreas: new insights.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2011-08-02       Impact factor: 43.330

5.  Cytosolic and mitochondrial malic enzyme isoforms differentially control insulin secretion.

Authors:  Rebecca L Pongratz; Richard G Kibbey; Gerald I Shulman; Gary W Cline
Journal:  J Biol Chem       Date:  2006-11-13       Impact factor: 5.157

6.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

7.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

8.  Why expression of some genes is disallowed in beta-cells.

Authors:  Roel Quintens; Nico Hendrickx; Katleen Lemaire; Frans Schuit
Journal:  Biochem Soc Trans       Date:  2008-06       Impact factor: 5.407

9.  Secreted semaphorin 5A suppressed pancreatic tumour burden but increased metastasis and endothelial cell proliferation.

Authors:  A Sadanandam; S S Sidhu; S Wullschleger; S Singh; M L Varney; C-S Yang; A E Ashour; S K Batra; R K Singh
Journal:  Br J Cancer       Date:  2012-07-10       Impact factor: 7.640

10.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Authors:  Jason I Herschkowitz; Karl Simin; Victor J Weigman; Igor Mikaelian; Jerry Usary; Zhiyuan Hu; Karen E Rasmussen; Laundette P Jones; Shahin Assefnia; Subhashini Chandrasekharan; Michael G Backlund; Yuzhi Yin; Andrey I Khramtsov; Roy Bastein; John Quackenbush; Robert I Glazer; Powel H Brown; Jeffrey E Green; Levy Kopelovich; Priscilla A Furth; Juan P Palazzo; Olufunmilayo I Olopade; Philip S Bernard; Gary A Churchill; Terry Van Dyke; Charles M Perou
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  48 in total

Review 1.  Molecular subtypes in cancers of the gastrointestinal tract.

Authors:  Maarten F Bijlsma; Anguraj Sadanandam; Patrick Tan; Louis Vermeulen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-04-12       Impact factor: 46.802

2.  Antitumor Effects of Anti-Semaphorin 4D Antibody Unravel a Novel Proinvasive Mechanism of Vascular-Targeting Agents.

Authors:  Iratxe Zuazo-Gaztelu; Marta Pàez-Ribes; Patricia Carrasco; Laura Martín; Adriana Soler; Mar Martínez-Lozano; Roser Pons; Judith Llena; Luis Palomero; Mariona Graupera; Oriol Casanovas
Journal:  Cancer Res       Date:  2019-06-25       Impact factor: 12.701

Review 3.  Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.

Authors:  Gitta Boons; Timon Vandamme; Marc Peeters; Guy Van Camp; Ken Op de Beeck
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

4.  Transcriptional alterations in hereditary and sporadic nonfunctioning pancreatic neuroendocrine tumors according to genotype.

Authors:  Xavier M Keutgen; Suresh Kumar; Sudheer Kumar Gara; Myriem Boufraqech; Sunita Agarwal; Ralph H Hruban; Naris Nilubol; Martha Quezado; Richard Finney; Maggie Cam; Electron Kebebew
Journal:  Cancer       Date:  2017-11-17       Impact factor: 6.860

Review 5.  Consensus guidelines for the use and interpretation of angiogenesis assays.

Authors:  Patrycja Nowak-Sliwinska; Kari Alitalo; Elizabeth Allen; Andrey Anisimov; Alfred C Aplin; Robert Auerbach; Hellmut G Augustin; David O Bates; Judy R van Beijnum; R Hugh F Bender; Gabriele Bergers; Andreas Bikfalvi; Joyce Bischoff; Barbara C Böck; Peter C Brooks; Federico Bussolino; Bertan Cakir; Peter Carmeliet; Daniel Castranova; Anca M Cimpean; Ondine Cleaver; George Coukos; George E Davis; Michele De Palma; Anna Dimberg; Ruud P M Dings; Valentin Djonov; Andrew C Dudley; Neil P Dufton; Sarah-Maria Fendt; Napoleone Ferrara; Marcus Fruttiger; Dai Fukumura; Bart Ghesquière; Yan Gong; Robert J Griffin; Adrian L Harris; Christopher C W Hughes; Nan W Hultgren; M Luisa Iruela-Arispe; Melita Irving; Rakesh K Jain; Raghu Kalluri; Joanna Kalucka; Robert S Kerbel; Jan Kitajewski; Ingeborg Klaassen; Hynda K Kleinmann; Pieter Koolwijk; Elisabeth Kuczynski; Brenda R Kwak; Koen Marien; Juan M Melero-Martin; Lance L Munn; Roberto F Nicosia; Agnes Noel; Jussi Nurro; Anna-Karin Olsson; Tatiana V Petrova; Kristian Pietras; Roberto Pili; Jeffrey W Pollard; Mark J Post; Paul H A Quax; Gabriel A Rabinovich; Marius Raica; Anna M Randi; Domenico Ribatti; Curzio Ruegg; Reinier O Schlingemann; Stefan Schulte-Merker; Lois E H Smith; Jonathan W Song; Steven A Stacker; Jimmy Stalin; Amber N Stratman; Maureen Van de Velde; Victor W M van Hinsbergh; Peter B Vermeulen; Johannes Waltenberger; Brant M Weinstein; Hong Xin; Bahar Yetkin-Arik; Seppo Yla-Herttuala; Mervin C Yoder; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2018-08       Impact factor: 9.596

Review 6.  New Genetics and Genomic Data on Pancreatic Neuroendocrine Tumors: Implications for Diagnosis, Treatment, and Targeted Therapies.

Authors:  Anja M Schmitt; Ilaria Marinoni; Annika Blank; Aurel Perren
Journal:  Endocr Pathol       Date:  2016-09       Impact factor: 3.943

7.  24-Hydroxycholesterol participates in pancreatic neuroendocrine tumor development.

Authors:  Matias Soncini; Gianfranca Corna; Marta Moresco; Nadia Coltella; Umberto Restuccia; Daniela Maggioni; Laura Raccosta; Chin-Yo Lin; Francesca Invernizzi; Roberto Crocchiolo; Claudio Doglioni; Catia Traversari; Angela Bachi; Rosa Bernardi; Claudio Bordignon; Jan-Åke Gustafsson; Vincenzo Russo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-26       Impact factor: 11.205

Review 8.  Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.

Authors:  Elvira Pelosi; Germana Castelli; Ugo Testa
Journal:  Biomedicines       Date:  2017-11-18

9.  miR-431 Promotes Metastasis of Pancreatic Neuroendocrine Tumors by Targeting DAB2 Interacting Protein, a Ras GTPase Activating Protein Tumor Suppressor.

Authors:  Tiantian Zhang; Soyoung Choi; Tuo Zhang; Zhengming Chen; Yudan Chi; Shixia Huang; Jenny Z Xiang; Yi-Chieh Nancy Du
Journal:  Am J Pathol       Date:  2020-01-14       Impact factor: 4.307

10.  Identification of CD90 as Putative Cancer Stem Cell Marker and Therapeutic Target in Insulinomas.

Authors:  Floryne O Buishand; Ger J A Arkesteijn; Laurien R Feenstra; Claire W D Oorsprong; Margiet Mestemaker; Achim Starke; Ernst-Jan M Speel; Jolle Kirpensteijn; Jan A Mol
Journal:  Stem Cells Dev       Date:  2016-05-05       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.